Follow The Filings

PLX Protalix Biotherapeutics Inc.

Health Care, filed as PROTALIX BIOTHERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 exit

In 2026 Q2 James Silverman sold out of Protalix Biotherapeutics.

Who owns PLX

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management exited 2026 Q2 Last 2026 Q1 0.10% Exit −0.10% 340,000 $738K History

0 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by PLX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PLX insider trades
  • $101K bought by 1 insider
  • $314 sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Dror Bashan CEO
    Buy
    $101K 56,000 shares at $1.81 +42% to stake
    Traded Dec 19, 2025 Filed Dec 23, 2025
    ↗
  2. Amos Bar-Shalev Director
    Sale
    $314 168 shares at $1.87 100% of stake
    Traded Nov 18, 2025 Filed Nov 19, 2025
    ↗

SEC filings

Recent issuer filings from EDGAR, 21 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 15 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $65.49M $53.4M $52.74M
Gross profit * $42.51M $29.08M $25.75M
Gross margin * 64.9% 54.5% 48.8%
Net income $8.31M $2.93M -$6.6M
Net margin * 12.7% 5.5% -12.5%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $69.93M $60.08M $66.67M
Total non-current assets * $14.5M $13.34M $15.67M
Total assets $84.43M $73.42M $82.35M
Total current liabilities $45.53M $25.62M $26.52M
Total non-current liabilities $5.34M $4.58M $7.6M
Total equity $33.57M $43.21M $48.23M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$1.32M $8.67M -$11.99M
Cash from investing -$16.71M $4.22M -$2.37M
Cash from financing $24.67M -$16.79M $9.33M
Net change in cash $6.52M -$3.87M -$5.08M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.